Raytech / Raybestos Corporation Asbestos Trust Fund Claims

Raytech and Raybestos Trust Facts

Raybestos, Raymark and Raytech Relationship

The page URL uses Raytech and Raybestos because those names are connected through the corporate history behind the asbestos liabilities. The governing TDP formally defines claims by reference to asbestos-containing products for which Raymark Industries, Inc. and its predecessors and affiliates have legal liability that could be asserted against Raytech.

Raybestos-Manhattan and later Raymark were known for friction products used in automotive and industrial applications, including asbestos-containing brake and clutch materials. The formal bankruptcy trust, however, is named for Raytech Corporation.

For claim accuracy, a claimant should identify the actual covered product, operation, exposure period and corporate relationship rather than assuming that every product carrying a similar Raybestos or Raymark name automatically establishes Trust eligibility.

Bankruptcy and Trust History

Federal government research identifies Raymark Corp./Raytech Corp. as filing bankruptcy on March 10, 1989, with reorganization confirmation on August 31, 2000. Raytech later emerged from bankruptcy in April 2001.

Raytech’s SEC filings explain that the reorganization established the Raytech Asbestos Personal Injury Settlement Trust and entered a channeling injunction permanently directing future asbestos-related claims against Raytech and its subsidiaries to the Trust for resolution.

The Trust later engaged Claims Processing Facility, Inc. to process asbestos personal-injury claims. CPF’s current Raytech page states that the Trust processes, liquidates and pays valid claims in accordance with the Third Amended and Restated Trust Distribution Procedures.

Current Adjusted Disease Values

On July 31, 2024, the Trustees issued an official adjustment to the liquidated values in Schedule B of the TDP to reflect Consumer Price Index increases. The notice states that these adjusted values apply to all outstanding and future offers:

The older $125,000 Mesothelioma figure remains the underlying Schedule B value in the TDP, but the official July 2024 notice increased the value to $179,760. This page therefore does not present $125,000 as the current liquidated value.

Need help now? Call 800.291.0963
Live chat available 24/7, 365 days a year.
Submit Your Case

Current 1.35% Pro-rata Percentage

An official Trustee notice dated November 19, 2024 increased the Trust’s Pro-rata Percentage from 0.92% to 1.35%, effective November 14, 2024. CPF continues to display that notice as the Trust’s current payment-percentage update.

The Trustees determine the percentage using estimates of the number, type and value of present and future claims, available Trust assets and liquidity, administrative and legal expenses, and other factors affecting the Trust’s ability to treat present and future claimants comparably.

Mathematical illustration only — not a guaranteed payment. $179,760 current adjusted Mesothelioma value × 1.35% = approximately $2,426.76. $59,249 Lung Cancer value × 1.35% = approximately $799.86. Actual eligibility and payment remain subject to the TDP, claim review, releases and applicable limitations.

Medical and Exposure Requirements

Malignant Mesothelioma Category I requires a qualifying diagnosis by a physician or board-certified pathologist, meaningful and credible exposure to Raytech Product/Operations before December 31, 1982, and evidence of a 10-year latency period between first asbestos exposure and diagnosis.

Lung Cancer Category II requires a primary lung-cancer diagnosis, medical support showing asbestos exposure as a contributing factor, evidence of an underlying asbestos-related disease, qualifying Raytech exposure before December 31, 1982, and the latency requirements of the TDP.

Other Cancer and Severely Disabling Asbestosis have their own medical and exposure criteria. CPF also maintains Trust-specific approved jobsite and presumptive-occupation resources to assist with exposure review.

Claim Filing and Processing

Claims are filed through the Claims Processing Facility using Raytech-specific proof-of-claim materials. CPF provides Raytech filing instructions, claim forms, approved-jobsite resources, presumptive occupations, physician information, deficiency codes and other Trust documents.

The filing instructions require claimants to provide the information and documentation necessary to place the claim in the correct disease category and establish qualifying exposure. Once a claim is reviewed and approved, payment is made after the Trust receives an executed release, subject to the current Pro-rata Percentage.

The Trust’s TDP is designed to provide fair, equitable, prompt and inexpensive treatment of present and future PI Trust Claims in substantially the same manner.

Other and Special Claim Categories

The Raytech TDP separates the four disease categories currently receiving scheduled liquidated values from lower-priority asbestos disease categories and also provides procedures for certain specialized claims.

The governing procedures address Extraordinary Claims, Exigent Health Claims, Extreme Hardship Claims, Indirect Claims, releases and dispute-resolution procedures. Special treatment depends on satisfying the particular requirements of the TDP.

The Trust’s public materials reviewed for this build did not provide a sufficiently current 2025 or 2026 audited annual financial statement from which to verify current total assets, 2025 claims paid or cumulative dollars paid. The latest primary annual-report figures independently located were older and are therefore not substituted for current statistics.

Confirmed Primary Sources for Trust Facts

No law-firm or lead-generation website was used as factual authority for this page. Primary and government materials reviewed include:

• Official Claims Processing Facility Raytech Trust page.
• Official Raytech Third Amended and Restated Asbestos Personal Injury Settlement Trust Distribution Procedures.
• Official November 19, 2024 notice increasing the Pro-rata Percentage to 1.35%.
• Official July 31, 2024 notice establishing adjusted liquidated disease values.
• Official Raytech claim filing instructions.
• Official CPF Raytech approved-jobsite resources.
• Raytech SEC filing describing the bankruptcy reorganization, Trust and channeling injunction.
• Federal bankruptcy-court record concerning Raytech, Raymark and the Raytech Asbestos Personal Injury Trust.

Get Help Reviewing a Raytech / Raybestos Asbestos Claim

Call 800.291.0963

Live chat is available 24/7, 365 days a year.

Submit Your Case

Work involving Raybestos, Raymark or related brake, clutch or friction products does not automatically establish Trust eligibility or compensation. Eligibility depends on diagnosis, qualifying covered exposure, medical documentation, the applicable TDP criteria, filing requirements and individual circumstances. Compensation is not guaranteed.